Pfizer and Regeneron Q1 Earnings Analysis by Evan Seigerman

Regeneron's Q1 Performance

• 📉 Regeneron experienced significant misses across the board, particularly with its EIA and EIA HD treatments for eye conditions like macular degeneration.
• ⚠️ Concerns are high regarding the durability of Regeneron's core business due to competition from Roche and the emergence of biosimilars.
• ⏳ The company is awaiting the performance of pipeline assets later in the year, which are crucial for future growth.
• 💊 Regeneron's COVID-19 antibody treatment, previously taken by Trump, is no longer authorized.

Pfizer's Q1 Results and Outlook

• 📊 Pfizer reported a decent quarter, slightly missing on the topline but showing strong progress in expense management.
• ⚠️ There are ongoing concerns about Pfizer's ability to maintain its dividend, though it is not expected to be cut at this time.
• 📈 Pfizer is forecasting EPS guidance at the higher end of its range, which is encouraging.
• 🚫 Questions are anticipated regarding the discontinued obesity pill, Danuglipron, which was a significant development.

Pharmaceutical Industry Trends

• 🌍 Merck is moving $1.5 billion of Keytruda manufacturing to the United States from Ireland, citing complex biologic production and potential tariff avoidance.
• 💰 European countries are being urged to increase their pharmaceutical pricing to better reflect the innovation brought by drug companies, as they currently undervalue these contributions.
• 🏥 A key focus for Medicare is whether it will begin covering obesity drugs, a decision that carries significant cost implications.
• ⚖️ The potential impact of the IRA drug pricing and most-favored-nation pricing on the biopharma community is a significant ongoing discussion.